Understanding the role of chondrocytes in osteoarthritis: utilizing proteomics

Expert Rev Proteomics. 2019 Mar;16(3):201-213. doi: 10.1080/14789450.2019.1571918. Epub 2019 Jan 31.

Abstract

Proteomic analyses have been acknowledged to carry a significant prospective in elucidating the pathogenesis of several diseases, including osteoarthritis (OA). But it has not been an easy road: major technical issues, mainly derived from the complex and rigid nature of the cartilage tissue, had to be faced; an obstacle that led to the development of different approaches. Areas covered: In this review, we categorized the proteomic studies undertaken (proteomic analyses of the cartilage, cartilage explants, cultured chondrocytes, and chondrocytes' secretome) as part of the different strategies developed in order to overcome tissue and disease-specific challenges. Essentially these approaches aimed at identifying differences in the proteome of healthy vs diseased tissue. Our aim was to point out the novel players that have emerged from these analyses and highlight the associated mechanism(s) suggested to play a role in the pathogenesis of OA. Expert commentary: The identified factors indicate the implication of age-associated mechanisms, such as metabolic deregulation, inflammation, and redox imbalance, in OA onset and/or progression. Taken together these results outline the causal network of the disease and place chondrocytes' senescence at the center of the emerging aetiopathological atlas.

Keywords: Aging; cartilage; chondrocyte; extracellular matrix (ECM); osteoarthritis; proteomics; secretome; senescence.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cellular Senescence / genetics
  • Chondrocytes / metabolism
  • Chondrocytes / pathology
  • Humans
  • Inflammation / genetics*
  • Inflammation / pathology
  • Osteoarthritis / genetics*
  • Osteoarthritis / pathology
  • Osteoarthritis / therapy
  • Oxidation-Reduction
  • Proteome / genetics*
  • Proteomics*

Substances

  • Proteome